Cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer and application

A technology of hydroxycamptothecin and crizotinib, applied in the field of medicine, can solve problems such as tumors that have not been seen in combination with HCPT and crizotinib, and achieve the effects of improving effect, enhancing curative effect and reducing side effects

Inactive Publication Date: 2018-12-28
TIANJIN UNIV OF SCI & TECH
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the combination of HCPT and Crizotinib for the treatment of tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer and application
  • Cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer and application
  • Cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] The experimental results of HCPT and Crizotinib monomers inhibiting the proliferation of H460, H1975 and HCC827 cells are shown in the figure, and the ICs of HCPT and Crizotinib monomers in the three kinds of cells 50 The values ​​are shown in Table 1 below.

[0049] Table 1 IC of HCPT and Crizotinib on lung cancer cells 50 value

[0050]

Embodiment 2

[0052] Dilute HCPT and Crizotinib with dimethyl sulfoxide respectively to the concentrations in the table. The experimental results of the inhibitory effect on proliferation of different concentrations of HCPT and Crizotinib when used alone are shown in Figure 1-3 and Table 2-4.

[0053] Table 2 HCPT to the cell survival rate of H460

[0054]

[0055] Table 3 Crizotinib on the cell viability of H460

[0056]

[0057] Table 4 Cell survival rate and CI value of HCPT combined with Crizotinib on H1460

[0058]

[0059] Combination drugs can have synergistic effect, antagonistic effect and additive effect. Generally, the combination index CI is used to judge the specific effect. CI1 means that the combination of the two drugs has an antagonistic effect. It can be seen from the above results that when HCPT and Crizotinib are administered at the same time, the CI value can reach <1 at a certain dose ratio, and at this time, the combined use of the two has a better synerg...

Embodiment 3

[0061] Dilute HCPT and Crizotinib with dimethyl sulfoxide respectively to the concentrations in the table. The experimental results of the inhibitory effect on proliferation of different concentrations of HCPT and Crizotinib when used alone are shown in Figure 4-6 and Table 5-7.

[0062] Table 5HCPT to the cell survival rate of H1975

[0063]

[0064] Table 6 Crizotinib on the cell viability of H1975

[0065]

[0066] Table 7 The cell survival rate and CI value of H1975 combined with HCPT and Crizotinib

[0067]

[0068] Combination drugs can have synergistic effect, antagonistic effect and additive effect. Generally, the combination index CI is used to judge the specific effect. CI1 means that the combination of the two drugs has an antagonistic effect. It can be seen from the above results that when HCPT and Crizotinib are administered at the same time, the CI value can reach <1 at a certain dose ratio. At this time, the combination of the two has a better syner...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer and application. Active components of the medicinal composition include a chemotherapy medicine 10-hydroxycamptothecine and a targeting medicine crizotinib. The invention also relates to application of 10-hydroxycamptothecine and crizotinib in the field of cancer treatment drugs. According tothe cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer, the anti-tumor medicine 10-hydroxycamptothecine and the targeting medicine crizotinib are used in match; the in vitro experiment verifies that the chemotherapy medicine 10-hydroxycamptothecine and the targeting medicine crizotinib are obviously synergistically interacted in killing malignant cells. The new application of the drug combination helps reducing the toxic and side effects of chemotherapy medicines; the drug resistance of the targeting medicine can also be reduced; the tumor inhibiting effect is improved; and scientific foundation is supplied to develop new drugs.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the use of a drug combination with synergistic antitumor effect 10-hydroxycamptothecin combined with crizotinib for treating non-small cell lung cancer. Background technique [0002] As the most common primary malignant tumor of the lung, lung cancer has a high incidence rate, rapid disease spread, and high mortality rate. It ranks first among malignant tumors in many countries and regions, and continues to show an upward trend. It is one of the main causes of cancer-related deaths one. [0003] In the past 50 years, many countries have reported that the morbidity and mortality of lung cancer have increased significantly. The incidence and mortality of lung cancer in men rank first among all malignant tumors, and the incidence and mortality of lung cancer occupy the second place in women. According to incomplete statistics, as of 2017, the number of lung cancer case...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4745A61K31/4545A61P35/00
CPCA61K31/4545A61K31/4745A61P35/00A61K2300/00
Inventor 刘振郁彭谢伟然付青山殷盼盼
Owner TIANJIN UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap